IMR-687 for Sickle Cell Disease

Recruiting at 6 trial locations

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Imara, Inc.

Disqualifiers: Hepatitis B, Hepatitis C, HIV, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

30 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing IMR-687, a medication, in adult patients with Sickle Cell Anemia who were in a previous study. It aims to see if the medication is safe and well-tolerated by monitoring side effects and body responses.

Who Is on the Research Team?

Karen Tang, MD

Principal Investigator

Imara, Inc.

Are You a Good Fit for This Trial?

This trial is for adults with Sickle Cell Anemia who finished the IMR-SCD-102 study. Participants must be able to consent, not pregnant or likely to become so, and have normal kidney and liver function tests. They can't join if they have severe anemia or high hemoglobin levels, active hepatitis B/C, malaria events, or HIV.

Inclusion Criteria

I am not pregnant, not breastfeeding, and unlikely to get pregnant.

I am a male and unlikely to father a child.

I understand the study and can sign the consent form.

Exclusion Criteria

eGFR <50 mL/min

AST/ALT > 3x the upper limit of normal

Subjects with Hb >12.5 g/dL or <6 g/dL

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Open-label Extension

Participants receive IMR-687 to evaluate long-term safety and tolerability

49 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• IMR-687

Trial Overview The trial is testing the long-term safety and effects of a drug called IMR-687 in adults with Sickle Cell Anemia who previously completed a related Phase 2a study.

How Is the Trial Designed?

Group I: Open Label Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

Imara, Inc.

Lead Sponsor

Trials

6

Recruited

430+